| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
This compound does not have a specific biological target; it functions as a chemical building block for peptide synthesis. As a phenylalanine analogue, it is used to introduce sterically hindered 2-methylphenylalanine residues into peptides. This modification can significantly alter peptide conformation, hydrophobicity, and receptor binding affinity, making it valuable for structure-activity relationship studies and the development of peptide-based therapeutics.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value is as a research chemical and building block. Amino acid derivatives like this one are used commercially as ergogenic supplements that affect anabolic hormone release and muscle protection. |
| ln Vivo |
This compound is not administered in vivo as a therapeutic agent. It is a research chemical utilized as a building block in peptide synthesis. The final deprotected peptide product, not this intermediate, would be the subject of in vivo pharmacological testing for therapeutic efficacy and safety.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable as this compound is not biologically active. Its use is in organic synthesis. A typical protocol involves its use as a building block in solid-phase peptide synthesis (SPPS) or solution-phase peptide coupling, where the amino group can be coupled to other amino acids using standard coupling reagents (e.g., HATU, DIC) after appropriate protection strategies.
|
| Cell Assay |
This compound is not used in cell-based assays. Its applications are in synthetic chemistry. It should be stored as a powder at -20°C or below, and it is recommended to use it within one month after dissolving in solvent. Information concerning product stability, particularly in solution, has rarely been reported.
|
| Animal Protocol |
In vivo animal experiments do not involve this compound as a test article. It is a chemical intermediate used in the synthesis of drug candidates. If used to synthesize a therapeutic peptide, that final product would be subjected to animal testing. The methylated phenylalanine itself is not administered to animals as a test compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable as this is not a drug. It is a small molecule (MW 179.22 g/mol) with the formula C10H13NO2. Its properties are relevant for chemical handling and storage. It is a chiral amino acid derivative with (S)-configuration at the α-carbon.
|
| Toxicity/Toxicokinetics |
The toxicity of this compound is not extensively documented. As a research chemical, it should be handled with standard laboratory precautions. It is not intended for human or veterinary use. The product is for research purposes only and should be handled in a well-ventilated area with appropriate personal protective equipment.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-845.
|
| Additional Infomation |
(2S)-2-amino-3-(2-methylphenyl)propanoic acid is a derivative of L-phenylalanine, specifically L-phenylalanine with a methyl group substituted at the 2-position of the benzene ring. It belongs to the toluene class of compounds and is also a derivative of L-phenylalanine.
H-Phe(2-Me)-OH is a valuable building block for the synthesis of conformationally constrained peptides. The ortho-methyl substitution introduces steric hindrance that can restrict rotation around the phenyl ring, potentially enhancing peptide stability and selectivity. It is not a pharmaceutical and has no clinical trials or approved therapeutic status. |
| Molecular Formula |
C10H13NO2
|
|---|---|
| Molecular Weight |
179.22
|
| Exact Mass |
179.094
|
| CAS # |
80126-53-0
|
| PubChem CID |
2761493
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
326.2±30.0 °C at 760 mmHg
|
| Flash Point |
151.1±24.6 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.568
|
| LogP |
1.57
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
182
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(C1C=CC=CC=1C)[C@H](N)C(=O)O
|
| InChi Key |
NHBKDLSKDKUGSB-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C10H13NO2/c1-7-4-2-3-5-8(7)6-9(11)10(12)13/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(2-methylphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5797 mL | 27.8987 mL | 55.7973 mL | |
| 5 mM | 1.1159 mL | 5.5797 mL | 11.1595 mL | |
| 10 mM | 0.5580 mL | 2.7899 mL | 5.5797 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
